Zimbabwe has turned down a significant American health deal worth $367m (£272m) spanning five years over the United States' demand for confidential data.
This rejection came to light following a internal memorandum dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the agreement was "skewed".
A government spokesman has since clarified that the United States was demanding access to genetic material for scientific study and profit but refused to share the benefits from future medical innovations.
"We are forced to start the challenging and unfortunate task of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged continued talks to reach a agreement acceptable to all parties so the country's critical HIV treatment initiative can be sustained.
Wider Context
This development follows a comparable case in neighbouring Kenya, where a high court blocked a related deal with the US after legal challenges were filed about the security of citizens' health data.
After returning to office recently, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump argued its spending was "inefficient" and his administration was seeking government-to-government agreements to boost transparency and accountability.
According to statements, 16 African countries have so far signed similar health pacts, constituting over $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership might have yielded significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving antiretroviral therapy through American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to surrender its biological resources and data over an extended period, without any corresponding assurance of access to any scientific breakthroughs – such as new medicines or tests – that could be developed from that provided information," Mangwana explained.
"In essence, our nation would provide the basic resources for scientific discovery without any assurance that the final treatments would be accessible to our population if a future disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its push of one-on-one deals were undermining structures previously established through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to deal with potential pandemics.
"This system is designed to guarantee that when a nation provides its information, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to develop them."
The government's concerns over the US deal "must not be interpreted as opposition to America," he added.
"We welcome ongoing discussions with our American counterparts on how subsequent co-operation might be designed in a way that honours the sovereignty and dignity of each country."
Health Experts Reaction
Medical experts stated it acknowledged the official position, but recommended that talks should continue given that much of the country's HIV programmes depended on international support.
"Where specific concerns arise, including those involving data governance or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," the group added.
The halted deal underscores the ongoing challenges between accepting much-needed international aid and protecting national sovereignty in an ever more data-driven world.